Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | LCK | P06239 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7497706 | 0.84 | KDM4E (0.39) | CA1CA2NAMPTKMT2AKDM4E | |
| SCHEMBL1480730 | 0.82 | KDM4E (0.39) | KMT2AKDM4ELMNAHSD17B10TSHR | |
| SCHEMBL15558268 | 0.79 | AKT1 (0.36) | CA1CA2CYP17A1ATRKDM4E | |
| SCHEMBL19508908 | 0.78 | TUBB4A (0.35) | HSD17B10TSHRF2MAPT | |
| SCHEMBL9088000 | 0.77 | — | — | |
| SCHEMBL10175725 | 0.77 | MAPT (0.46) | CA1CA2KMT2AKDM4ELMNA | |
| SCHEMBL8194625 | 0.77 | CA1 (0.35) | CA1CA2 | |
| SCHEMBL15617029 | 0.77 | AKT1 (0.34) | CA1CA2CYP17A1KDM4EHSD17B10 | |
| SCHEMBL19508907 | 0.76 | TUBB4A (0.48) | KDM4ELMNAHSD17B10ALDH1A1 | |
| SCHEMBL10379725 | 0.76 | RECQL (0.45) | KMT2AKDM4EHSD17B10NPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155862-A1 | Process for the preparation of 2-hydroxymethyl-pyrrolidine-3,4-diols | LONZA AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-1379676-B1 | PROCESS FOR THE PREPARATION OF 2-HYDROXYMETHYL-PYROLIDINE-3,4-DIOLS | LONZA AG (CH) | 2006-05-24 | — | — | EP | disclosed |
| US-20040185539-A1 | Process for the preparation of 2-hydroxymethyl-pyrolidine 3, 4-diols | LONZA AG (CH) | 2004-09-23 | — | — | US | disclosed |
| EP-1379676-A2 | PROCESS FOR THE PREPARATION OF 2-HYDROXYMETHYL-PYROLIDINE-3,4-DIOLS | LONZA AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6576780-B1 | Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors | GD SEARLE & COMPANY | 2003-06-10 | — | — | US | disclosed |
| WO-2002074737-A2 | PROCESS FOR THE PREPARATION OF 2-HYDROXYMETHYL-PYROLIDINE-3,4-DIOLS | LONZA AG (CH) | 2002-09-26 | — | — | WO | disclosed |
| US-6207708-B1 | FOR THERAPY AND PROPHYLAXIS OF AUTOIMMUNE AND/OR INFLAMMATORY CONDITIONS AFFECTING THE JOINTS SUCH AS ARTHRITIS, AND INFLAMMATORY BOWEL DISEASE, CARDIVASCULAR ISCHEMIA, DIABETES, CONGESTIVE HEART FAILURE, MYOCARDITIS, ATHEROSCLEROSIS, | G. D. SEARLE & COMPANY | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040185539-A1 | Process for the preparation of 2-hydroxymethyl-pyrolidine 3, 4-diols | HPD, DHPS, DPYD | CA1 2103/4885CA2 2059/4885CYP17A1 1108/4885 |
| US-20090155862-A1 | Process for the preparation of 2-hydroxymethyl-pyrrolidine-3,4-diols | HPD, DHPS, DPYD | CA1 1920/4885CA2 2406/4885CYP17A1 1656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.